Bevacizumab Effect on Blood Velocity

Retinal blood flow velocity is affected by Bevacizump intravitreal injection. This effect is correlated to treatment success.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Choroidal Neovascularization Choroid Diseases Eye Diseases Metaplasia Neovascularization, Pathologic Pathologic Processes Pathological Conditions, Signs and Symptoms Uveal Diseases

Sex eligibility

All sexes

Study type

Observational

Primary location

Tel aviv sourasky medical center

Tel Aviv, 64239, Israel

About this study

The purpose of the study was to carry out a pilot study on the short-term effect of intravitreal Bevacizumab (Avastin) injection on retinal blood-flow velocity and test whether the short-term haemodynamic changes could predict the longer term clinical result of the treatment.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Patients with CNV receiving Bevacizumab intravitreal injection

Exclusion criteria

Candidates in whom the retina could not be seen clearly because of media opacity or a poorly dilating pupil

Treatment and study plan

Primary outcomes

Blood flow velocity change

Time frame: 1 day following injection

Sponsors and collaborators

Lead sponsor

Optical Imaging, Ltd.

Industry

Registry information

Official study title

The Effect of Intravitreal Bevacizumab (Avastin) Injection on Retinal Blood-Flow Velocity in Patients With Choroidal Neovascularization

Important dates

Study start: 2008
Primary completion: 2008
Study completion: 2008
First posted: Feb 17, 2011
Registry last updated: Feb 17, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed